The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.
 
Arsen Osipov
No Relationships to Disclose
 
Aleksandra Popovic
No Relationships to Disclose
 
Alexander Hopkins
No Relationships to Disclose
 
Garrett M. Frampton
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Lee A. Albacker
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals
Consulting or Advisory Role - AMAG Pharmaceuticals; Dava Oncology
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Intensity Therapeutics; Merck (Inst); Syndax (Inst)
 
Daniel A. Laheru
No Relationships to Disclose
 
Lei Zheng
Stock and Other Ownership Interests - Z and L International Medical
Consulting or Advisory Role - AstraZeneca; Biosynergies; Merck; Merrimack; novarock
Research Funding - Amgen; Bristol-Myers Squibb; Gradalis; Halozyme; ITeos Therapeutics; Merck
Patents, Royalties, Other Intellectual Property - GVAX, licensed to Aduro Biotech.
 
Elizabeth M. Jaffee
Consulting or Advisory Role - Adaptive Biotechnologies; CStone Pharmaceuticals; Dragonfly Therapeutics; Genocea Biosciences; Incyte
Research Funding - Aduro Biotech; Amgen; Bristol-Myers Squibb; Corvus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genocea Biosciences; MedImmune
 
Mark Yarchoan
Consulting or Advisory Role - Eisai; Exelixis
Research Funding - Bristol-Myers Squibb; Exelixis; Merck